抗tnf - α药物——进入主流?

Future Prescriber Pub Date : 2009-12-24 DOI:10.1002/fps.55

Tina Ding MSc, MRCP, Chris Deighton BMedSci, MD, FRCP

{"title":"抗tnf - α药物——进入主流?","authors":"Tina Ding MSc, MRCP, Chris Deighton BMedSci, MD, FRCP","doi":"10.1002/fps.55","DOIUrl":null,"url":null,"abstract":"<p>Anti-TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease-modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti-TNF-alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"6-8"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.55","citationCount":"0","resultStr":"{\"title\":\"Anti-TNF-alpha drugs - moving into the mainstream?\",\"authors\":\"Tina Ding MSc, MRCP, Chris Deighton BMedSci, MD, FRCP\",\"doi\":\"10.1002/fps.55\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Anti-TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease-modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti-TNF-alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"10 4\",\"pages\":\"6-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.55\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.55\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anti-TNF-alpha drugs - moving into the mainstream?

Anti-TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease-modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti-TNF-alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量